Having just completed the Top Picks report for 2007 – the 24th consecutive year I have surveyed the newsletter advisors for their favorite stocks -- I thought I would share some observations to help readers best use the information in this feature.

And over the next few days, I will post articles to share observations on the stocks and sectors chosen, discuss the participating advisors, and highlight some of last year's top performers to help guide you in assessing this year's report.

I'll begin today by noting some caveats that should be kept in mind by those who are considering buying stocks from among the list of Top Picks. The advisors who have participated in this year's project were asked to submit a favorite speculative and/or conservative stock for the year ahead.

Each year Steven Halpern, editor of TheStockAdvisors.com, surveys the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is part of his 24th annual Top Picks Report.

Millennium Pharmaceuticals (NASDAQ: MLNM) is the top speculative idea for 2007 from Ryan Detrick, editor of Players Performer. He says, "Millennium is one of the top performing stocks in the biotechnology field, as the equity has gained more than 44% since May 2006.

"The Cambridge, Massachusetts-based firm focuses on treatments for cancer and inflammatory diseases. The company also has drugs in the pipeline for multiple sclerosis, Crohn's disease, and various cancers. The biotech sector as a whole is positioned very nicely for a move higher.

"The overwhelming sentiment from investors toward this technical outperformer is one of doubt and skepticism, which parlays perfectly into a contrarian outlook. Specifically, heavy skepticism levied against a stock that is attractive from a technical perspective, not to mention a security from a solidly performing sector as a whole, suggests that there is ample sideline money to help usher the shares even higher.